Skip to main content
TipRanks
Go Ultimate75% OFF

Epsilon Healthcare Limited (EPN) AI Stock Analysis

7 Followers
AU:EPN

Epsilon Healthcare Limited

(ASX:EPN)

Select Model
Rating:54Neutral
Price Target:AUD 0.03▲(13.04% Upside)
Action:reiterated
Date:09/24/26

The overall score of 54 reflects a high-risk, early-stage turnaround. The primary positive driver is strong technical momentum, with the stock price trending well above its moving averages. This is offset by significant fundamental concerns: a highly leveraged balance sheet and a very expensive valuation, with a P/E of 93.3 that leaves no room for error. The company's recent operational stabilization and positive cash flow are encouraging but remain fragile.

Positive Factors
Revenue and Gross Margin ImprovementThe combination of strong revenue growth and a materially higher gross margin indicates improving scale and product economics. If maintained, this operating progress can strengthen contribution from each dollar of sales and provide a foundation for future profitability over the next several quarters.
Negative Factors
Weak Operating ProfitabilityRevenue and gross margin are improving, but the company still lacks a meaningful operating profit buffer. Negative EBIT means further execution or cost pressure could quickly affect earnings, while the near-zero net margin leaves limited capacity to absorb setbacks.

Epsilon Healthcare Limited (EPN) vs. iShares MSCI Australia ETF (EWA)

-40%-20%0%20%40%60%AU:EPN-4.17%EWA+8.37%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
AUD 3.89M
Dividend Yield
―
Average Volume (3M)
206.59K
Price to Earnings (P/E)
76.7
Beta (1Y)
-0.30
Revenue Growth
121.40%
EPS Growth
―
Country
Australia
Employees
14
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Epsilon Healthcare Limited Business Overview & Revenue Model

Company Description

Epsilon Healthcare Limited operates as an Australian-based healthcare and pharmaceutical firm, with significant operations also extending into Canada. Established in 2016 and headquartered in Sydney, the company specializes in several areas: manufact...

How the Company Makes Money

null

Epsilon Healthcare Limited Financial Statement Overview

Summary

Financial performance shows a nascent turnaround with positive TTM net income and strong cash flow recovery, but is weighed down by a highly leveraged balance sheet and compressed gross margins. The overall picture is one of stabilization with significant fragility.

Income Statement

45Neutral

Balance Sheet

35Negative

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMDec 2025Jun 2025Dec 2024Dec 2022Dec 2021
Income Statement
Total Revenue20.37M9.39M5.60M6.65M7.11M5.50M
Gross Profit6.92M2.09M4.17M4.81M725.85K2.06M
EBITDA-694.10K-1.86M-2.13M-937.07K-10.86M-8.03M
Net Income96.58K-1.28M-3.25M-1.09M-13.29M-9.24M
Balance Sheet
Total Assets19.47M17.87M22.26M14.41M20.50M30.55M
Cash, Cash Equivalents and Short-Term Investments1.29M242.86K1.57M343.01K809.60K2.34M
Total Debt8.69M10.35M7.88M3.45M3.20M4.44M
Total Liabilities15.59M15.95M11.57M6.87M11.23M10.98M
Stockholders Equity3.88M1.91M10.70M7.54M9.27M19.57M
Cash Flow
Free Cash Flow975.73K-3.30M-3.50M-803.47K-3.10M-6.18M
Operating Cash Flow1.12M-3.13M-3.41M-703.37K-2.57M-5.43M
Investing Cash Flow-703.93K6.29M-97.73K-99.12K-529.40K-737.59K
Financing Cash Flow131.29K-4.48M4.73M335.91K1.61M1.47M

Epsilon Healthcare Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price0.02

Price Trends

50DMA0.02Negative
100DMA0.02Negative
200DMA0.02Negative

Market Momentum

MACD0.00Negative
RSI49.29Neutral
STOCH66.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EPN, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of 0.00 indicates Negative momentum. The RSI at 49.29 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EPN.

Epsilon Healthcare Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

AU:EPN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:VLSAU:VLS77OutperformAUD 142.75M13.0019.91%5.58%12.19%22.36%
AU:MVPAU:MVP60NeutralAUD 46.19M75.891.13%―8.99%450.00%
AU:EPNAU:EPN54NeutralAUD 9.73M76.673.34%―121.40%―
AU:LGPAU:LGP52NeutralAUD 54.65M-14.35-1.67%―15.21%-141.82%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:IDTAU:IDT43NeutralAUD 19.03M-7.19-13.81%―5.93%66.32%
AU:PKPAU:PKP39UnderperformAUD 18.75M-5.074388.00%―-19.73%50.34%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%50%AU:EPNAU:VLSAU:LGPAU:MVPAU:PKPAU:IDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
AU:EPN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
AU:EPNEpsilon Healthcare Limited0.02-0.00-4.17%
AU:VLSVita Life Sciences Limited2.600.2912.70%
AU:LGPLittle Green Pharma Ltd.0.07-0.07-52.86%
AU:MVPMedical Developments International Limited0.42-0.10-18.27%
AU:PKPAlthea Group Holdings Ltd.0.01-0.01-35.00%
AU:IDTIDT Australia Limited0.05-0.01-22.03%

Epsilon Healthcare Limited Corporate Events

Epsilon Healthcare lifts quarterly receipts 34% as diversified platform gains scale

Oct 30, 2026

Epsilon Healthcare Limited reported strong growth for the quarter ended 30 September 2026, with customer receipts of $3.9 million, up 34 percent on the prior year’s corresponding quarter. The performance was driven by rising demand across its contrac...

Epsilon Healthcare lifts revenue and builds integrated medicinal cannabis platform

Sep 27, 2026

Epsilon Healthcare reported a sharp turnaround in the first half of 2026, with revenue rising 123% to $7.59 million, positive EBITDA of $255,000, and net operating cash flow of $1.03 million, helped by stronger operating performance and lower one-off...

Epsilon Healthcare Clarifies Managing Director Loan Was Unsecured

Sep 24, 2026

Epsilon Healthcare has clarified that a loan from its Managing Director, previously described as “secured” in several quarterly Appendix 4C cash flow reports, was in fact unsecured at all times. The company confirmed that no security interest or char...

Epsilon Healthcare Director Boosts Equity Stake Through On-Market Share Purchase

Sep 17, 2026

Epsilon Healthcare Limited has disclosed a change in the shareholding of director Zoe Hutchings, in line with ASX listing rule requirements. The filing details her direct interests in fully paid ordinary shares and confirms that there were no changes...

Epsilon Healthcare Director Alan Beasley Boosts Shareholding via On-Market Purchases

Sep 10, 2026

Epsilon Healthcare Limited has disclosed a change in the holdings of director Alan Preston Beasley, who increased his direct stake in the company through on-market purchases. Over several transactions on 3, 4 and 10 September 2026, Beasley acquired 1...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Sep 24, 2026